MULTIFOCAL MICRONODULAR PNEUMOCYTE HYPERPLASIA

This adverse event was reported 34 times

MULTIFOCAL MICRONODULAR PNEUMOCYTE HYPERPLASIA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 RILUZOLE 1 0.0004
1 ARSENIC TRIOXIDE 1 0.0004
2 DOCETAXEL ANHYDROUS 24 0.0004
3 DOCETAXEL 24 0.0004
4 TRASTUZUMAB 20 0.0003
5 GEMTUZUMAB OZOGAMICIN 1 0.0003
6 MYCOPHENOLATE MOFETIL 22 0.0002
7 MYCOPHENOLATE MOFETIL HYDROCHLORIDE 22 0.0002
8 ANTI-THYMOCYTE GLOBULIN (RABBIT) 1 0.0001
9 SIROLIMUS 1 0.0001
See all drugs enriched for association with MULTIFOCAL MICRONODULAR PNEUMOCYTE HYPERPLASIA

MULTIFOCAL MICRONODULAR PNEUMOCYTE HYPERPLASIA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Interleukin-5 Antagonist [EPC] 1 0.0015
1 Benzothiazole [EPC] 1 0.0004
2 CD33-directed Immunoconjugate [EPC] 1 0.0003
3 HER2/neu Receptor Antagonist [EPC] 20 0.0003
4 Microtubule Inhibitor [EPC] 24 0.0001
5 Vasopressin V2 Receptor Antagonist [EPC] 1 0.0001
6 Alkylating Drug [EPC] 13 0.0001
7 Antimetabolite Immunosuppressant [EPC] 1 0.0000
8 Ester Local Anesthetic [EPC] 1 0.0000
9 Corticosteroid [EPC] 24 0.0000
See all drug classes enriched for association with MULTIFOCAL MICRONODULAR PNEUMOCYTE HYPERPLASIA